Fredrik Piehl

Active 1990–2026

192
Papers
23,950
Citations
82
h-index
184
i10-index

Citations

Citations per year for Fredrik Piehl1976: 2 citations1991: 3 citations1992: 3 citations1993: 4 citations1994: 1 citations1995: 3 citations1996: 14 citations1997: 17 citations1998: 10 citations1999: 20 citations2000: 24 citations2001: 28 citations2002: 36 citations2003: 44 citations2004: 46 citations2005: 45 citations2006: 52 citations2007: 34 citations2008: 49 citations2009: 36 citations2010: 36 citations2011: 20 citations2012: 47 citations2013: 52 citations2014: 57 citations2015: 75 citations2016: 90 citations2017: 110 citations2018: 138 citations2019: 735 citations2020: 1,174 citations2021: 1,385 citations2022: 1,279 citations2023: 1,009 citations2024: 1,819 citations2025: 939 citations2026: 26 citations1977–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,480 citing papers, 18.4% of this breakdownUnited Kingdom: 1,193 citing papers, 8.9% of this breakdownGermany: 1,010 citing papers, 7.5% of this breakdownItaly: 883 citing papers, 6.6% of this breakdownSweden: 853 citing papers, 6.3% of this breakdownChina: 825 citing papers, 6.1% of this breakdownCanada: 515 citing papers, 3.8% of this breakdownSwitzerland: 503 citing papers, 3.7% of this breakdownSpain: 489 citing papers, 3.6% of this breakdownFrance: 452 citing papers, 3.4% of this breakdownNetherlands: 443 citing papers, 3.3% of this breakdownAustralia: 397 citing papers, 3% of this breakdown
0%18.4%Other 25.4%

Fields

  • Medicine62.9%
  • Neuroscience14%
  • Biochemistry, Genetics and Molecular Biology13.9%
  • Immunology and Microbiology6.8%
  • Engineering0.3%
  • Nursing0.3%
  • Other1.8%

Topics

  • Multiple Sclerosis Research Studies10.7%
  • Neuroinflammation and Neurodegeneration Mechanisms4%
  • Peripheral Neuropathies and Disorders3.8%
  • Amyotrophic Lateral Sclerosis Research3.6%
  • Alzheimer's disease research and treatments2.5%
  • T-cell and B-cell Immunology2.1%
  • Other73.3%

Coauthors

All papers

Open in search
  1. Neurofilaments as biomarkers in neurological disorders

    Authors: , , , , , , , , , , , , , - Nature Reviews Neurology 2018 cited by 1,971

  2. Multiple sclerosis

    Authors: , , , , , , - Nature Reviews Disease Primers 2018 cited by 1,398

  3. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vincent Damotte, Bertrand Fontaine, Léna Guillot‐Noël, Mark Lathrop, Sandra Vukusic, Achim Berthele, Viola Pongratz, Dorothea Buck, Christiane Gasperi, Christiane Graetz, Verena Grummel, Bernhard Hemmer, Muni Hoshi, Benjamin Knier, Thomas Korn, Christina M. Lill, Felix Luessi, Mark Mühlau, Frauke Zipp, Efthimios Dardiotis, Cristina Agliardi, Antonio Amoroso, Nadia Barizzone, Maria Donata Benedetti, Luisa Bernardinelli, Paola Cavalla, Ferdinando Clarelli, Gıancarlo Comı, Daniele Cusi, Federica Esposito, Laura Ferrè, Daniela Galimberti, Clara Guaschino, Maurizio Leone, Vittorio Martinelli, Lucia Moiola, Marco Salvetti, Melissa Sorosina, Domizia Vecchio, Andrea Zauli, Silvia Santoro, Nicasio Mancini, Miriam Zuccalà, Julia Mescheriakova, Cornelia M. van Duijn, Steffan D. Bos, Elisabeth Gulowsen Celius, Anne Spurkland, Manuel Comabella, Xavier Montalbán, Lars Alfredsson, Izaura Lima Bomfim, David Gómez-Cabrero, Jan Hillert, Maja Jagodic, Magdalena Lindén, Fredrik Piehl, Ilijas Jelčić, Roland Martinꝉ, Mirela Sospedra, Amie Baker, Maria Ban, Clive Hawkins, Pirro G. Hysi, Seema Kalra, Fredrik Karpe, Jyoti Khadake, Geneviève Lachance, Paul Molyneux, Matthew Neville and 57 more - Science 2019 cited by 1,456

  4. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stefanie Aeschbacher, Muhamed Barakovic, Andreas Buser, Andrew Chan, Giulio Disanto, Marcus D'Souza, Renaud Du Pasquier, Oliver Findling, Riccardo Galbusera, Kevin Hrusovsky, Michael Khalil, Johannes Lorscheider, Amandine Mathias, Annette Orleth, Ernst-Wilhelm Radue, Reza Rahmanzadeh, Tim Sinnecker, Suvitha Subramaniam, Jochen Vehoff, Sven Wellmann, Jens Wuerfel, Chiara Zecca - The Lancet Neurology 2022 cited by 601

  5. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Jonsson, Ludwig Kappos, Mohsen Khademi, Michael Khalil, Jens Kühle, Mikael Landén, Ville Leinonen, Giancarlo Logroscino, Ching‐Hua Lu, Jan Lycke, Nadia Magdalinou, Andrea Malaspina, Niklas Mattsson, Lieke Meeter, Sanjay R. Mehta, Signe Modvig, Tomas Olsson, Ross W. Paterson, Josué Pérez‐Santiago, Fredrik Piehl, Yolande A.L. Pijnenburg, Okko T. Pyykkö, Óskar Ragnarsson, Julio C. Rojas, Jeppe Romme Christensen, Linda Sandberg, Carole Scherling, Jonathan M. Schott, Finn Sellebjerg, Isabella Laura Simone, Tobias Skillbäck, Morten Stilund, Peter Sundström, Anders Svenningsson, Rosanna Tortelli, Carla Tortorella, Alessandro Trentini, Maria Troiano, Martin R. Turner, John C. van Swieten, Mattias Vågberg, Marcel M. Verbeek, Luisa María Villar, Pieter Jelle Visser, Anders Wallin, Andreas Weiss, Carsten Wikkelsø, Edward J. Wild - JAMA Neurology 2019 cited by 760

  6. Neurofilaments as biomarkers in neurological disorders — towards clinical application

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Reviews Neurology 2024 cited by 372

  7. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fredrik Piehl, Marco Battaglini, Urs Fischer, Ludwig Kappos, Claudio Gobbi, Cristina Granziera, Claire Bridel, David Leppert, Aleksandra Maleska Maceski, Pascal Benkert, Jens Kühle - JAMA Neurology 2023 cited by 275

  8. Locus for severity implicates CNS resilience in progression of multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gıancarlo Comı, Chris Cotsapas, Bruce Cree, Sandra D’Alfonso, Efthimios Dardiotis, Philip L. De Jager, Silvia Delgado, Bénédicte Dubois, Sinah Engel, Federica Esposito, Marzena J. Fabis‐Pedrini, Massimo Filippi, Kathryn C. Fitzgerald, Christiane Gasperi, Lissette Gomez, Refujia Gomez, Georgios M. Hadjigeorgiou, Jörg Hamann, Friederike Held, Roland G. Henry, Jan Hillert, Jesse Huang, Inge Huitinga, Talat Islam, Noriko Isobe, Maja Jagodic, Allan G. Kermode, Michael Khalil, Trevor J. Kilpatrick, Ioanna Konidari, Karim L. Kreft, Jeannette Lechner‐Scott, Maurizio Leone, Felix Luessi, Sunny Malhotra, Ali Manouchehrinia, Clara P. Manrique, Filippo Martinelli Boneschi, Andrea C. Martinez, Viviana Martínez-Maldonado, Elisabetta Mascia, Luanne M. Metz, Luciana Midaglia, Xavier Montalbán, Jorge R. Oksenberg, Tomas Olsson, Annette Oturai, Kimmo Pääkkönen, Grant P. Parnell, Nikolaos A. Patsopoulos, Margaret A. Pericak‐Vance, Fredrik Piehl, Justin P. Rubio, Adam Santaniello, Silvia Santoro, Catherine Schaefer, Finn Sellebjerg, Hengameh Shams, Klementy Shchetynsky, Cláudia Silva, Vasileios Siokas, Helle Bach Søndergaard, Melissa Sorosina, Bruce Taylor, Marijne Vandebergh, Elena S. Vasileiou, Domizia Vecchio, Margarete M. Voortman, Howard L. Weiner, Dennis Wever and 21 more - Nature 2023 cited by 227

  9. Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cell 2018 cited by 523

  10. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels

    Authors: , , , , , , - Annals of Clinical and Translational Neurology 2020 cited by 247

  11. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alasdair Coles, Jan Hillert, Fredrik Piehl, Helmut Butzkueven, Tomáš Kalinčík - The Lancet Neurology 2020 cited by 438

  12. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jerrica Farias, Rita Frangiomore, Sarah Heintsman, Robert H.P. de Meel, Manisha Chopra, Paolo Emilio Alboini, Angela Genge - Neurology 2019 cited by 288

  13. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

    Authors: , , , , , , , , , , , , , , , , , , , , - JAMA Neurology 2022 cited by 194

  14. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

    Authors: , , , , , , , , , , , , , , , - JAMA Neurology 2019 cited by 509

  15. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

    Authors: , , , , , , , , , , , - Neurology 2017 cited by 428

  16. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis

    Authors: , , , , , , , , , - JAMA Neurology 2021 cited by 234

  17. Risk factors for amyotrophic lateral sclerosis

    Authors: , , , , - Clinical Epidemiology 2015 cited by 454

  18. Inflammation-related plasma and CSF biomarkers for multiple sclerosis

    Authors: , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2020 cited by 197

  19. Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

    Authors: , , , , , , , , , , , , , , - Nature Communications 2023 cited by 94

  20. Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ann Herman, Christopher Harp, Amit Bar‐Or - JAMA Neurology 2024 cited by 92

  21. T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression

    Authors: , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 109

  22. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2022 cited by 124

  23. DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elisabeth Gulowsen Celius, Helle Bach Søndergaard, Jesper Tegnér, Hanne F. Harbo, Annette Oturai, Sigurgeir Ólafsson, Hannes P. Eggertsson, Bjarni V. Halldórsson, Haukur Hjaltason, Elías Ólafsson, Ingileif Jónsdóttir, Kāri Stefánsson, Tomas Olsson, Fredrik Piehl, Tomas J. Ekström, Ingrid Kockum, Andrew P. Feinberg, Maja Jagodic - Nature Communications 2018 cited by 212

  24. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes

    Authors: , , , , , , , , , , , , , , , , - Nature Communications 2019 cited by 142